Background: Tacrolimus is the most common calcineurin inhibitor given to kidney and liver transplant recipients. Prolonged-release once-daily tacrolimus (LCPT) is the newest formulation of this drug, but prescribing practices for tacrolimus across Canada are unknown.
Objectives: To investigate the use of tacrolimus across Canada, by determining coverage for the drug, exploring prescribing practices and factors related to decision-making, and identifying management methods for patients with rapid metabolism of tacrolimus.